Biomarkers as Surrogate Endpoints in Cancer Trials

Continual changes in the science of cancer diagnosis and prevention demand rigorous scientific knowledge of the professional nurse to optimize the outcome of cancer prevention drug/agent development and the delivery of evidence-based care.